Elaine Siegfried, M.D., is professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, St. Louis, Mo. She also is a member of the Dermatology Times Editorial Advisory board and a co-medical editor.
Sustaining a socioeconomically inclusive dermatology practiceMarch 26th 2019
Most dermatologists train in a clinical setting that accepts underinsured patients, but only some physicians continue along this path. Elaine Siegfried, M.D. offers her point of view on the pros and cons of working with this population, and discusses how to maintain a socioeconomically inclusive dermatology practice.
Should you wait after isotretinoin to treat acne with laser?December 4th 2015
Dermatology Times editorial advisor, Dr. Elaine Siegfried continues the discussion on isotretinoin with Jim Leyden, M.D., emeritus professor of dermatology at the University of Pennsylvania. In this final segment, the two discuss whether a waiting period is necessary before treating acne scars and the questionable existence of pityrosporum folliculitis.
Isotretinoin’s discovery and developmentSeptember 17th 2015
Dermatology Times editorial advisor Dr. Elaine Siegfried talks with Jim Leyden, M.D., emeritus professor of dermatology at the University of Pennsylvania about the art and science of isotretinoin therapy. Dr. Leyden, aside from being a member of the famed Acne Mafia, was a really active participant in the drug development process for isotretinoin, a drug for which, the institutional memory about that process may be fading. The two discuss many of the important initial clinical observations and those that others have made over the years.
Takeaway: Considering alternativesJanuary 15th 2015
Dermatology Times editorial advisor, Elaine Siegfried, M.D., talks with Peter Lio, M.D., assistant professor of clinical dermatology and pediatrics at Northwestern University’s Feinberg School of Medicine, and private practice, Dermatology and Aesthetics of Wicker Park, Wicker Park, Chicago, about his interest in alternative medicine and the legitimacy and usefulness of certain techniques and therapies.
Childhood skin disease has unique challengesSeptember 17th 2014
Therapeutics is one of the most significant challenges in pediatric dermatology. Children have been identified as “therapeutic orphans”, with few options that have FDA-approved pediatric indications. Access to new and novel treatments like biologics is especially limited. Supportive legislation, beginning with the Best Pharmaceuticals for Children Act (bpca.nichd.nih.gov), has marked the dawn of a new era.
Compiling baffling medical encounters proves a great way to copeAugust 1st 2012
We medical professionals are confronted with our own assortment of believe-it-or-nots and oddities on a daily basis. Unfortunately, they are often more upsetting or frustrating than astounding. I started keeping a list a few years ago, initially as a coping mechanism. But gradually, the list evolved into a collection.
Words of wisdom motivate, entertainApril 1st 2010
Shortly after I was invited to join the editorial board at Dermatology Times almost two years ago, I began collecting quotes to share with readers. Some are entertaining, some are inspiring. I heard some straight from the original source - often fellow dermatologists speaking publicly.
Pediatric psoriasis: Troubling news for children with inflammatory skin disease, and the physicians who treat themDecember 1st 2009
In September 2009, Amgen decided to withdraw application for expanded use of its biologic tumor necrosis factor (TNF) blocking agent etanercept (Enbrel) in pediatric patients with moderate-to-severe psoriasis.